Sunshine Biopharma Advances K1.1 mRNA Lipid Nanoparticle Program Toward Dual-Therapy Strategy for Lung Cancer
核心洞察
Sunshine Biopharma (搜索) reported that its K1.1 mRNA lipid nanoparticle demonstrated tumor-suppressing activity as a single agent in multiple in vivo hepatocellular carcinoma (搜索) models.
The K1.1 mRNA gene encodes a tumor suppressor frequently mutated in hepatocellular carcinoma (搜索), non-small cell lung cancer (搜索), and pancreatic cancer (搜索), where mutations create "cold" tumors that evade immune surveillance.
The company's next phase will combine K1.1 mRNA with a cancer vaccine in non-small cell lung cancer (搜索), aiming to convert "cold" tumors into "hot" tumors.
Sunshine Biopharma (搜索) Inc. (NASDAQ:SBFM) has outlined the next steps for its proprietary oncology initiative, the K1.1 mRNA lipid nanoparticle (LNP) program, reporting in vivo tumor suppression and advancing a dual-therapy strategy targeting difficult-to-treat cancers. The company, based in Fort Lauderdale, FL, announced the update on August 26, 2026, detailing preclinical results and a planned combination approach for non-small cell lung cancer (搜索) (NSCLC).
The gene encoding the K1.1 mRNA is a tumor suppressor that is frequently mutated in a variety of cancers, including hepatocellular carcinoma (搜索) (HCC), non-small cell lung cancer (搜索), and pancreatic cancer (搜索). Mutations in the K1.1 gene create "cold" tumors that evade host immunosurveillance. In NSCLC and pancreatic cancers, a limited set of oncogenes is predominantly associated with mutations in the K1.1 gene, contributing to poor treatment prognosis.
Preclinical Results Support Tumor Suppressor Restoration
Sunshine Biopharma (搜索) reported that its results to date demonstrate the K1.1 mRNA LNP can be successfully delivered systemically in vivo. The candidate has been shown to be well tolerated and capable of restoring expression of the target tumor suppressor in grafted liver tumors in a dose-dependent manner.
Proof-of-concept studies further indicated that K1.1 mRNA exhibits tumor-suppressing activity in vivo as a single agent in at least two orthotopic HCC mouse models. In addition, the company obtained in vitro evidence that delivery of K1.1 mRNA alone exerts antiproliferative effects in several NSCLC cell lines.
Dual-Therapy Strategy for Non-Small Cell Lung Cancer
The next step in the program is to deliver K1.1 mRNA concurrently with a cancer vaccine targeting the associated antigens in vivo for the treatment of NSCLC. The company's stated goal with this dual-therapy approach is to transform "cold" tumors into "hot" tumors and suppress tumor growth, while simultaneously applying a cancer vaccine directed against the set of oncogenes associated with the K1.1 gene mutations.
"Our K1.1 mRNA program continues to deliver encouraging results that validate our tumor suppressor restoration strategy," said Steve Slilaty, CEO of Sunshine Biopharma (搜索). "The next phase—pairing K1.1 mRNA with a cancer vaccine—positions us to pursue a differentiated therapeutic pathway in NSCLC. Sunshine Biopharma is focused on bringing forward innovations that change the trajectory of difficult to treat cancers."
Commercial Footprint and Development Pipeline
Beyond its proprietary oncology program, Sunshine Biopharma (搜索) currently has 60 generic prescription drugs on the market in Canada, with approximately 12 additional drugs scheduled to be launched in the remainder of 2026. The company's proprietary drug development program comprises two core assets: K1.1 mRNA, an mRNA-lipid nanoparticle targeted for liver cancer, and a PLpro protease inhibitor (搜索), a small molecule for the treatment of SARS coronavirus infections.